Scholarlink

Background <p>The COVID-19 pandemic affected healthcare management for people with multiple sclerosis (PwMS), leading to alterations in disease-modifying therapies (DMTs) due to concerns about COVID-19 outcomes and vaccine efficacy.</p> Objectives <p>To compare DMT prescription patterns in PwMS before, during, and after the COVID-19 pandemic.</p> Methods <p>PwMS from the German MS Register, between 2019 and 2024, either newly diagnosed (Cohort A) or who discontinued or switched DMT (Cohort B), were analyzed over a follow-up period of 3&#xa0;months. Data from the pre-pandemic period were compared to early-, late-, and post-pandemic periods. DMTs were categorized as medium efficacy (meDMT) or high efficacy (heDMT).</p> Results <p>In Cohort A (<i>n</i> = 1810), pre-pandemic 46% had no DMT&#xa0;within 3 months of diagnosis, 39% received meDMT, and 15% heDMT (7.5% B cell-depleting therapies (BCD)). heDMT use increased during later periods (“early” 19%, “late” 29%, “post” 41%), with a shift toward BCD. In cohort B (<i>n</i> = 4246), pre-pandemic 47% paused DMT, 19% switched to meDMT, and 34% to heDMT (17% BCD). heDMT use also rose during the pandemic (“early” 37%, “late” 47%, “post” 48%), with increased BCD use.</p> Conclusions <p>There were no delays in DMT initiation or resumption during the pandemic with a notable increase in heDMT and BCD use, reflecting growing confidence in these treatment options.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

MS treatment trends before, during, and after the COVID-19 pandemic: insights from the German MS Register

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月26日

查看全文
  • Agni-Maria Konitsioti,
  • Sarah Laurent,
  • David Ellenberger,
  • Alexander Stahmann,
  • Paulus Rommer,
  • Judith Haas,
  • Clemens Warnke

摘要

Background

The COVID-19 pandemic affected healthcare management for people with multiple sclerosis (PwMS), leading to alterations in disease-modifying therapies (DMTs) due to concerns about COVID-19 outcomes and vaccine efficacy.

Objectives

To compare DMT prescription patterns in PwMS before, during, and after the COVID-19 pandemic.

Methods

PwMS from the German MS Register, between 2019 and 2024, either newly diagnosed (Cohort A) or who discontinued or switched DMT (Cohort B), were analyzed over a follow-up period of 3 months. Data from the pre-pandemic period were compared to early-, late-, and post-pandemic periods. DMTs were categorized as medium efficacy (meDMT) or high efficacy (heDMT).

Results

In Cohort A (n = 1810), pre-pandemic 46% had no DMT within 3 months of diagnosis, 39% received meDMT, and 15% heDMT (7.5% B cell-depleting therapies (BCD)). heDMT use increased during later periods (“early” 19%, “late” 29%, “post” 41%), with a shift toward BCD. In cohort B (n = 4246), pre-pandemic 47% paused DMT, 19% switched to meDMT, and 34% to heDMT (17% BCD). heDMT use also rose during the pandemic (“early” 37%, “late” 47%, “post” 48%), with increased BCD use.

Conclusions

There were no delays in DMT initiation or resumption during the pandemic with a notable increase in heDMT and BCD use, reflecting growing confidence in these treatment options.